Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200627 | 0.98 | KDM4E (0.73) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL22984077 | 0.98 | KDM4E (0.73) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL608623 | 0.98 | KDM4E (0.73) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL1525045 | 0.93 | KDM4E (0.64) | KDM4EMAPK1HIF1AADRA1APAOX | |
| Hexamethylenebisacetamide SCHEMBL9437043 | 0.85 | KDM4E (0.84) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL751437 | 0.85 | — | — | |
| Trifluoroacetic Acid SCHEMBL27664340 | 0.85 | ADRA1A (0.59) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL860791 | 0.84 | KDM4E (0.94) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL13902111 | 0.83 | KDM4E (0.71) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL18902856 | 0.83 | KDM4E (0.71) | KDM4EMAPK1HIF1AADRA1APAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | KDM4E 2817/4885MAPK1 1803/4885HIF1A 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.